NEW YORK (GenomeWeb News) – NextBio today announced a deal with the Winship Cancer Institute of Emory University to identify biomarkers and treatments for multiple myeloma.

The organizations will collaborate on a translational study using NextBio Clinical to interpret molecular data from patients with the disease, which constitutes only about 1 percent of all cancers in the US but has been especially difficult to treat. The goal of the study will be to make new discoveries that can improve care given to patients with refractory and relapsed forms of myeloma, NextBio said.